ESMO 2022: Highlights on neoadjuvant ICI in locally advanced dMMR colon cancer: The NICHE-2 study
Share.
About Author
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Related Posts
-
ESMO 2022: Highlights on sacituzumab govitecan in HR+/HER2- metastatic breast cancer: TROPiCS-02
-
ESMO 2022: Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma
-
ESMO 2022: Strong potential for neoadjuvant nivolumab plus ipilimumab to become standard of care for locally advanced MMR-deficient colon cancer